Companies / Seres Therapeutics, Inc.

Seres Therapeutics, Inc.

Nasdaq: MCRBCIK 1609809CAMBRIDGE, MA

Financials · FY2025

Revenue$789.0K
Net income$5.70M
Total debt$110.00M
Cash$15.59M
Diluted EPS$0.64
Shares outstanding9.9M

Ownership

9.9M shares outstanding · as of Aug 3, 2026
0.36%Insiders
Ownership
Insiders0.36%35,600
Institutions24.64%2,449,589
Public float75.00%7,456,072

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 7

View all →
Insider% of sharesShares
0.12%11,577
Young Teresa L.See Remarks
0.09%8,557
DesRosier ThomasSee Remarks
0.08%7,789
Henn Matthew RSee Remarks
0.08%7,677
Brady KellyFormerSee Remarks
Kender Richard NSee Remarks · Director
Thorell MarellaSee Remarks

Institutional holders 36

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
OMERS Administration Corporation
13F manager
ExitCommon Stock$-214.3K-14K
-100.00%
0
low
Q1 2026
as of
Marshall Wace, LLP
13F manager
AddCommon Stock$171.7K+19K
+16.11%
139,539
1.40% of shares
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
TrimCommon Stock$-100.3K-11K
-13.13%
74,835
0.75% of shares
low
Q4 2025
as of
Barclays PLC
13F manager
AddCommon Stock$89.6K+6K
+427.84%
7,432
0.07% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
TrimCommon Stock$-76.6K-5K
-96.35%
195
<0.01% of shares
low
Q1 2026
as of
Two Sigma Investments, LP
13F manager
TrimCommon Stock$-61.7K-7K
-27.01%
18,794
0.19% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
AddCommon Stock$58.2K+7K
+7.12%
111,000
1.12% of shares
low
Q3 2025
as of
Barclays PLC
13F manager
NewCommon Stock$27.1K+1K
1,408
0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
MCRBCommon StockEquity81750R201BBG0099X6859